MX344276B - Compuesto de piperidina novedoso o sal del mismo. - Google Patents
Compuesto de piperidina novedoso o sal del mismo.Info
- Publication number
- MX344276B MX344276B MX2014010395A MX2014010395A MX344276B MX 344276 B MX344276 B MX 344276B MX 2014010395 A MX2014010395 A MX 2014010395A MX 2014010395 A MX2014010395 A MX 2014010395A MX 344276 B MX344276 B MX 344276B
- Authority
- MX
- Mexico
- Prior art keywords
- group
- alkyl group
- salt
- substituent
- cancer agent
- Prior art date
Links
- -1 piperidine compound Chemical class 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012043303 | 2012-02-29 | ||
| JP2012186534 | 2012-08-27 | ||
| PCT/JP2013/055064 WO2013129443A1 (ja) | 2012-02-29 | 2013-02-27 | 新規ピペリジン化合物又はその塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014010395A MX2014010395A (es) | 2015-06-05 |
| MX344276B true MX344276B (es) | 2016-12-08 |
Family
ID=49082638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010395A MX344276B (es) | 2012-02-29 | 2013-02-27 | Compuesto de piperidina novedoso o sal del mismo. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9346787B2 (Direct) |
| EP (1) | EP2821406B1 (Direct) |
| JP (1) | JP5323289B1 (Direct) |
| KR (1) | KR101677823B1 (Direct) |
| CN (1) | CN104159893B (Direct) |
| AU (1) | AU2013227024B2 (Direct) |
| BR (1) | BR112014021519B1 (Direct) |
| CA (1) | CA2865875C (Direct) |
| DK (1) | DK2821406T3 (Direct) |
| ES (1) | ES2576497T3 (Direct) |
| HU (1) | HUE028495T2 (Direct) |
| IN (1) | IN2014DN07283A (Direct) |
| MX (1) | MX344276B (Direct) |
| MY (1) | MY169179A (Direct) |
| PL (1) | PL2821406T3 (Direct) |
| PT (1) | PT2821406T (Direct) |
| RU (1) | RU2581834C1 (Direct) |
| SG (1) | SG11201405318PA (Direct) |
| TW (1) | TWI485146B (Direct) |
| WO (1) | WO2013129443A1 (Direct) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI485146B (zh) * | 2012-02-29 | 2015-05-21 | Taiho Pharmaceutical Co Ltd | Novel piperidine compounds or salts thereof |
| US9012475B2 (en) | 2013-08-27 | 2015-04-21 | Taiho Pharmaceutical Co., Ltd. | Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor |
| KR101430209B1 (ko) * | 2014-03-06 | 2014-08-14 | 강원대학교산학협력단 | 단백질 키나아제 활성 측정 방법 및 이를 위한 키트 |
| TWI693218B (zh) * | 2014-11-14 | 2020-05-11 | 美商美國禮來大藥廠 | 極光ａ激酶抑制劑 |
| CN104758286B (zh) * | 2015-03-05 | 2016-09-14 | 南京工业大学 | 1-苄基-4-(2,4-二氯苯乙胺基)哌啶在制备抗肿瘤药物中的应用 |
| JP6937322B2 (ja) * | 2016-12-22 | 2021-09-22 | 大鵬薬品工業株式会社 | 置換ピペリジン化合物の塩 |
| WO2019230679A1 (ja) | 2018-05-29 | 2019-12-05 | 大鵬薬品工業株式会社 | 抗腫瘍剤及び腫瘍治療方法 |
| CN112239465A (zh) | 2019-07-16 | 2021-01-19 | 微境生物医药科技(上海)有限公司 | 极光激酶抑制剂及其用途 |
| CN112898292A (zh) * | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | 新型极光激酶抑制剂及其用途 |
| TWI785474B (zh) * | 2020-01-22 | 2022-12-01 | 大陸商北京加科思新藥研發有限公司 | 用作選擇性Aurora A抑制劑的新型雜環化合物 |
| TW202321215A (zh) * | 2021-07-28 | 2023-06-01 | 大陸商北京加科思新藥研發有限公司 | Aurora a 選擇性抑制劑的多晶型及其用途 |
| EP4504209A1 (en) | 2022-04-08 | 2025-02-12 | Eli Lilly and Company | Method of treatment including kras g12c inhibitors and aurora a inhibitors |
| WO2024088193A1 (en) * | 2022-10-26 | 2024-05-02 | Js Innopharm (Suzhou) Ltd. | Combination of aurora a and parp inhibitors for treatment of cancers |
| WO2024088192A1 (en) * | 2022-10-26 | 2024-05-02 | Js Innopharm (Suzhou) Ltd. | An aurora a inhibitor for use in treatments of cancers |
| CN121039117A (zh) * | 2023-05-05 | 2025-11-28 | 苏州信诺维医药科技股份有限公司 | 杂环类化合物、其药物组合物和其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1345925B1 (en) * | 2000-12-21 | 2006-05-17 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| AU2005297848B2 (en) * | 2004-10-29 | 2011-03-17 | Msd K.K. | Novel aminopyridine derivatives having selective Aurora-A inhibitory effect |
| GB0509227D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| CA2619517A1 (en) | 2005-08-18 | 2007-02-22 | Michael Mortimore | Pyrazine kinase inhibitors |
| EP1917258A2 (en) * | 2005-08-26 | 2008-05-07 | SmithKline Beecham Corporation | Pyrimidinyl-pyrazole inhibitors of aurora kinases |
| WO2007041358A2 (en) | 2005-09-30 | 2007-04-12 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| CA2645728A1 (en) * | 2006-03-20 | 2007-09-27 | Edward Boyd (Deceased) | Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents |
| CA2645583A1 (en) | 2006-03-20 | 2007-09-27 | F. Hoffman-La Roche Ag | Methods of inhibiting btk and syk protein kinases |
| JP2008081492A (ja) | 2006-08-31 | 2008-04-10 | Banyu Pharmaceut Co Ltd | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| GB0705656D0 (en) | 2007-03-23 | 2007-05-02 | Addex Pharmaceuticals Sa | Novel compounds E1 |
| AU2008266960A1 (en) | 2007-06-20 | 2008-12-24 | Merck Sharp & Dohme Corp. | Diphenyl substituted alkanes |
| JP5411152B2 (ja) * | 2008-02-22 | 2014-02-12 | Ｍｓｄ株式会社 | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| CA2755806A1 (en) | 2009-03-23 | 2010-09-30 | Msd K.K. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| EP2411011A4 (en) * | 2009-03-24 | 2012-08-15 | Msd Kk | NEW AMINO-PYRIDINE DERIVATIVES WITH SELECTIVE AURORA A INHIBITION |
| TWI485146B (zh) * | 2012-02-29 | 2015-05-21 | Taiho Pharmaceutical Co Ltd | Novel piperidine compounds or salts thereof |
-
2013
- 2013-02-26 TW TW102106767A patent/TWI485146B/zh active
- 2013-02-27 KR KR1020147023717A patent/KR101677823B1/ko active Active
- 2013-02-27 PT PT137552295T patent/PT2821406T/pt unknown
- 2013-02-27 HU HUE13755229A patent/HUE028495T2/hu unknown
- 2013-02-27 US US14/381,814 patent/US9346787B2/en active Active
- 2013-02-27 MY MYPI2014702424A patent/MY169179A/en unknown
- 2013-02-27 SG SG11201405318PA patent/SG11201405318PA/en unknown
- 2013-02-27 IN IN7283DEN2014 patent/IN2014DN07283A/en unknown
- 2013-02-27 AU AU2013227024A patent/AU2013227024B2/en active Active
- 2013-02-27 EP EP13755229.5A patent/EP2821406B1/en active Active
- 2013-02-27 DK DK13755229.5T patent/DK2821406T3/en active
- 2013-02-27 PL PL13755229.5T patent/PL2821406T3/pl unknown
- 2013-02-27 CN CN201380011842.0A patent/CN104159893B/zh active Active
- 2013-02-27 MX MX2014010395A patent/MX344276B/es active IP Right Grant
- 2013-02-27 ES ES13755229.5T patent/ES2576497T3/es active Active
- 2013-02-27 JP JP2013523421A patent/JP5323289B1/ja active Active
- 2013-02-27 WO PCT/JP2013/055064 patent/WO2013129443A1/ja not_active Ceased
- 2013-02-27 BR BR112014021519-7A patent/BR112014021519B1/pt active IP Right Grant
- 2013-02-27 CA CA2865875A patent/CA2865875C/en active Active
- 2013-02-27 RU RU2014138987/04A patent/RU2581834C1/ru active
-
2016
- 2016-04-18 US US15/131,372 patent/US10092556B2/en active Active
-
2018
- 2018-08-31 US US16/118,912 patent/US20180369224A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN07283A (Direct) | ||
| PH12014501486A1 (en) | Novel nicotinamide derivative or salt thereof | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| MX2014011829A (es) | Compuestos de piridinilideno n-sustituidos y derivados para combatir plagas de animales. | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| PH12014502721A1 (en) | IMIDAZO[1,2-b] PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | |
| PH12014501719A1 (en) | Pyridone derivatives | |
| SMT201300085B (it) | Composti di pirrolo | |
| MX2009004920A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1. | |
| EA201170096A1 (ru) | Замещенные производные пиримидона | |
| MX339668B (es) | Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina. | |
| MY145603A (en) | 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | |
| NZ710052A (en) | Novel pyrazol derivatives | |
| PH12012501385A1 (en) | Piperazine compound having a pgds inhibitory effect | |
| MX367772B (es) | Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk. | |
| MY206124A (en) | Pyrimidine compound or salt thereof | |
| MX2013007937A (es) | Nuevo derivado de indol o indazol o sal del mismo. | |
| MX2013007938A (es) | Compuesto biciclico novedoso o sal del mismo. | |
| MX2015010611A (es) | Nuevos derivados de dihidroquinolin-2-ona como inhibidores de la aldosterona-sintasa (citocromo p450, familia 11, subfamilia b, polipeptido 2 (cyp11b2) o citocromo p450, familia 11, subfamilia b, polipeptido 1 (cyp11b1)). | |
| MX2017003822A (es) | Compuestos de piridina. | |
| MY169869A (en) | Pyrrolidine-3-ylacetic acid derivative | |
| MY185421A (en) | Heterocyclic amide compound and herbicide | |
| NZ735032A (en) | Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same | |
| HK1247813A1 (zh) | 一种含有氨基乙腈化合物作为活性成分的抗癌剂 | |
| TW200637870A (en) | Novel pyrimidine nucleoside compound and salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |